Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1930

1.

Un gain d’efficacité mais des effets indésirables parfois graves.

Guéguen A, Gout O.

Rev Prat. 2016 Jan;66(1):44-50. French.

PMID:
30512399
2.

Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.

Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP.

Clin Ther. 2018 Nov 20. pii: S0149-2918(18)30506-X. doi: 10.1016/j.clinthera.2018.10.011. [Epub ahead of print]

PMID:
30470580
3.

Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.

Crescenzo F, Marastoni D, Zuco C, Pitteri M, Magliozzi R, Monaco S, Calabrese M.

Mult Scler Relat Disord. 2018 Nov 12;27:305-311. doi: 10.1016/j.msard.2018.11.009. [Epub ahead of print]

PMID:
30453199
4.

Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®.

Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Pia Sormani M, Ghezzi A.

Neurol Ther. 2018 Nov 10. doi: 10.1007/s40120-018-0116-x. [Epub ahead of print] No abstract available.

PMID:
30415358
5.

Letter to the Editor Regarding: A Comprehensive Review on Copemyl®.

Comi G, Nicoletti F, Canonico PL, Centonze D.

Neurol Ther. 2018 Nov 10. doi: 10.1007/s40120-018-0115-y. [Epub ahead of print] No abstract available.

PMID:
30415356
6.

Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregation.

Song JY, Larson NR, Thati S, Torres-Vazquez I, Martinez-Rivera N, Subelzu NJ, Leon MA, Rosa-Molinar E, Schöneich C, Forrest ML, Middaugh CR, Berkland CJ.

J Control Release. 2018 Nov 7;293:36-47. doi: 10.1016/j.jconrel.2018.11.007. [Epub ahead of print]

PMID:
30414463
7.

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis.

Hegen H, Walde J, Bsteh G, Auer M, Wurth S, Zinganell A, Di Pauli F, Deisenhammer F, Berger T.

Front Immunol. 2018 Oct 25;9:2435. doi: 10.3389/fimmu.2018.02435. eCollection 2018.

8.

The key role of T cells in Parkinson's disease pathogenesis and therapy.

Baird JK, Bourdette D, Meshul CK, Quinn JF.

Parkinsonism Relat Disord. 2018 Oct 28. pii: S1353-8020(18)30465-6. doi: 10.1016/j.parkreldis.2018.10.029. [Epub ahead of print] Review.

PMID:
30404763
9.

Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis.

Kim SH, Park MS, Kim W, Huh SY, Shin HJ, Hyun JW, Kim HJ.

J Clin Neurol. 2018 Oct 26. [Epub ahead of print]

10.

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.

Vakrakou AG, Tzanetakos D, Valsami S, Grigoriou E, Psarra K, Tzartos J, Anagnostouli M, Andreadou E, Evangelopoulos ME, Koutsis G, Chrysovitsanou C, Gialafos E, Dimitrakopoulos A, Stefanis L, Kilidireas C.

BMC Neurol. 2018 Oct 29;18(1):178. doi: 10.1186/s12883-018-1183-4.

11.

Drug-Induced Liver Injury: Highlights of the Recent Literature.

Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH.

Drug Saf. 2018 Oct 20. doi: 10.1007/s40264-018-0743-2. [Epub ahead of print] Review.

PMID:
30343418
12.

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.

Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A; NTD Study Group.

J Neurol. 2018 Dec;265(12):2980-2992. doi: 10.1007/s00415-018-9083-5. Epub 2018 Oct 16.

13.

Ulnar neuropathy after glatiramer acetate subcutaneous injection: Ultrasound findings.

Coraci D, Giovannini S, Loreti C, Padua L.

J Clin Pharm Ther. 2018 Oct 12. doi: 10.1111/jcpt.12773. [Epub ahead of print] No abstract available.

PMID:
30315577
14.

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis.

Kuerten S, Jackson LJ, Kaye J, Vollmer TL.

CNS Drugs. 2018 Nov;32(11):1039-1051. doi: 10.1007/s40263-018-0567-8. Review.

15.

Treatment of multiple sclerosis - success from bench to bedside.

Tintore M, Vidal-Jordana A, Sastre-Garriga J.

Nat Rev Neurol. 2018 Oct 12. doi: 10.1038/s41582-018-0082-z. [Epub ahead of print] Review.

PMID:
30315270
16.

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice.

Gallily R, Yekhtin Z.

Inflammopharmacology. 2018 Oct 5. doi: 10.1007/s10787-018-0536-3. [Epub ahead of print]

PMID:
30291491
17.

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.

Melendez-Torres GJ, Armoiry X, Court R, Patterson J, Kan A, Auguste P, Madan J, Counsell C, Ciccarelli O, Clarke A.

BMC Neurol. 2018 Oct 3;18(1):162. doi: 10.1186/s12883-018-1162-9.

18.

The Novel Effect of Immunomodulator-Glatiramer Acetate on Epileptogenesis and Epileptic Seizures.

Lai MC, Lin KM, Yeh PS, Wu SN, Huang CW.

Cell Physiol Biochem. 2018;50(1):150-168. doi: 10.1159/000493965. Epub 2018 Oct 2.

19.

The effect of disease modifying therapies on CD62L expression in multiple sclerosis.

Voortman MM, Greiner P, Moser D, Stradner MH, Graninger W, Moser A, Haditsch B, Enzinger C, Fuchs S, Fazekas F, Fessler J, Khalil M.

Mult Scler J Exp Transl Clin. 2018 Sep 20;4(3):2055217318800810. doi: 10.1177/2055217318800810. eCollection 2018 Jul-Sep.

20.

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.

Healy BC, Glanz BI, Zurawski JD, Mazzola M, Chitnis T, Weiner HL.

J Neurol Sci. 2018 Nov 15;394:127-131. doi: 10.1016/j.jns.2018.09.020. Epub 2018 Sep 17.

PMID:
30248571

Supplemental Content

Loading ...
Support Center